Pharma BD Deal Intelligence
Roche paid $46.8B for the 44% of Genentech it didn't already own, gaining full control of the world's premier biologics R&D engine. Avastin, Herceptin, and Rituxan were generating $25B+ combined annual revenue—a rare mega-deal that preserved the innovation it was buying.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Swiss drug maker Roche agreed Thursday to buy the 44 percent of biotech company Genentech it doesn't already own for $46.8 billion in cash, ending a sometimes…
Roche and Genentech today announced that they have entered into a merger agreement under which Roche will acquire the outstanding shares of Genentech that it…
Roche Holding completed a $46.8 billion acquisition of biotech firm Genentech in 2009, culminating over two decades of partnership and prioritizing…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Roche acquired the 44% of Genentech it did not already own for $46.8 billion ($95 per share), making Genentech a wholly-owned subsidiary. The deal gave Roche full control of Genentech's blockbuster oncology portfolio including Avastin, Herceptin, and Rituxan, and its world-leading biologics R&D platform.
Assessment window: 10yr post-close.
200K US cases/yr · $6.0B Global Anti-VEGF Ophthal (2009)
Lucentis for wet AMD and Xolair (anti-IgE for severe asthma) added non-oncology dimensions. Both multi-billion franchises.
Lucentis competed with off-label Avastin and Eylea. Roche developed Vabysmo (faricimab) as successor. Xolair co-promoted with Novartis.
150K US cases/yr · $7.0B Global Anti-VEGF Oncology (2009)
Avastin was first approved anti-angiogenesis cancer therapy (2004). Approved across CRC, lung, breast, kidney, brain. Peak >$7B.
Biosimilar competition from ~2020. Cyramza (Lilly), Zaltrap (Sanofi/Regeneron) competed. IO wave shifted paradigms.
80K US cases/yr · $10.0B Global Rituximab Market (2009)
Rituxan was first mAb approved for cancer (1997). Cumulative sales >$100B. One of history's best-selling drugs.
Gazyva (obinutuzumab) as next-gen anti-CD20. Biosimilar erosion from ~2019. Expanded with bispecifics (Lunsumio, Columvi).
55K US cases/yr · $8.0B Global HER2+ BC Market (2009)
Roche completed takeover of remaining 44% of Genentech for $46.8B in 2009. Genentech's HER2 franchise defined targeted cancer therapy.
Herceptin dominated HER2+ BC 1998-2019. Perjeta+Herceptin became SOC. Kadcyla added ADC option. Built world's largest oncology franchise.
Roche made its first bid of $89 per share for the 44% of Genentech it did not already own, but the Genentech board rejected the offer as inadequate, sparking months of hostile talks.
After raising its offer from $89 to $93 and finally to $95 per share, Roche reached agreement with Genentech board, ending a contentious eight-month negotiation for full ownership.
Roche completed its $46.8 billion acquisition of the remaining publicly held Genentech shares at $95 per share, making Genentech a wholly owned subsidiary of the Swiss pharma giant.
With the full acquisition, Roche gained access to Genentech approximately $10 billion cash pool and full control of its pipeline beyond 2015, securing long-term oncology leadership.
Roche financed the acquisition through record private bond issuances: $16.6 billion in the US, EUR 11.25 billion in Europe, and GBP 1.25 billion in UK -- largest ever in each market.
Genentech three flagship products Avastin, Herceptin, and Rituxan/MabThera generated approximately $22 billion in combined annual revenue at their 2016 peak before biosimilar erosion.
Genentech became the engine of Roche pharma division, generating $22B+ at peak from Avastin/Herceptin/Rituxan alone. Post-biosimilar, Genentech continues producing blockbuster successors.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Genentech, Inc. (Roche Group) (this deal) | 2009 | $46.8B | 72 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2009 deals · Roche Holding AG deals · Immunology deals